SCHEMBL3582671

SCHEMBL3582671

CC1CN(c2nc(Nc3ccc(S(=O)(=O)N(C)CCN(C)C)cc3)c3ncn(-c4cscn4)c3n2)CCO1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 1/20 0.39
CSNK1E P49674 1/20 0.39
CDK13 Q14004 1/20 0.39
CDK12 Q9NYV4 1/20 0.39
FLT3 P36888 6/20 0.34
ABL1 P00519 3/20 0.33
PDGFRA P16234 1/20 0.32
EGFR P00533 4/20 0.32
SRC P12931 3/20 0.32
ERBB2 P04626 1/20 0.32
MET P08581 1/20 0.32
PDGFRB P09619 1/20 0.32
KIT P10721 1/20 0.32
FGFR1 P11362 1/20 0.32
FLT1 P17948 1/20 0.32
FGFR2 P21802 1/20 0.32
EPHA2 P29317 1/20 0.32
EPHB2 P29323 1/20 0.32
KDR P35968 1/20 0.32
TRPV1 Q8NER1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1590513 0.88 CSNK1D (0.41) CSNK1DCSNK1ECDK13CDK12FLT3
SCHEMBL1590512 0.88 CSNK1D (0.41) CSNK1DCSNK1ECDK13CDK12FLT3
SCHEMBL1591535 0.87 EGFR (0.41) CSNK1DCSNK1ECDK13CDK12FLT3
SCHEMBL1591536 0.87 EGFR (0.41) CSNK1DCSNK1ECDK13CDK12FLT3
SCHEMBL3586473 0.86 CSNK1E (0.40) CSNK1DCSNK1ECDK13CDK12FLT3
SCHEMBL3589147 0.84 CSNK1D (0.46) CSNK1DCSNK1ECDK13CDK12
SCHEMBL4443143 0.84 CSNK1D (0.43) CSNK1DCSNK1ECDK13CDK12FLT3
SCHEMBL1591506 0.84 CSNK1D (0.41) CSNK1DCSNK1ECDK13CDK12FLT3
SCHEMBL1591791 0.82 CSNK1D (0.48) CSNK1DCSNK1ECDK13CDK12FLT3
SCHEMBL1590599 0.82 CSNK1D (0.41) CSNK1DCSNK1ECDK13CDK12FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100056494-A1 PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES IRM LLC (BM) 2010-03-04 US claimed
EP-2124954-A2 PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES IRM LLC (BM) 2009-12-02 EP claimed
WO-2008094737-A2 PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES IRM LLC (BM) 2008-08-07 WO claimed
US-20100056494-A1 PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES IRM LLC (BM) 2010-03-04 US disclosed
EP-2124954-A2 PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES IRM LLC (BM) 2009-12-02 EP disclosed
WO-2008094737-A2 PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES IRM LLC (BM) 2008-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056494-A1 PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES ADK, PNP, DCK CSNK1D 1542/4885CSNK1E 1264/4885CDK13 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.